Webcast CME

Biologic Therapies Summit XI Webcast Series

Emerging Treatments in iMIDS

Release date: July 10, 2025
Expiration date:
July 9, 2027

Estimated Time of Completion: 2 hours and 45 minutes

Session Agenda

Signal and the Noise: Safety in Rheumatology
Michael Putman, MD, MSci

PsA
Christopher Ritchlin, MD, MPH

Difficult to Treat RA (D2TRA)
Jack Cush, MD

Emerging treatments on Lupus nephritis
Michelle Petri, MD, MPH

Advances in the treatment of inflammatory myopathies
Rohit Aggarwal, MD, MS

Description

Biologic Therapies Summit XI Webcast Series, repurposed from the 2025 Biologic Therapies Summit XI, is designed for healthcare professionals seeking to deepen their understanding of cutting-edge treatments for immune-mediated inflammatory diseases.

Learning Objectives

  • Describe the process by which “safety signals” emerge.
  • Highlight case studies of where this has gone awry.
  • Recommend solutions for a forward-looking safety-agenda.
  • Examine the mechanism of action of Janus kinase (JAK) inhibitors in modulating immune responses, and identify the potential toxicities and adverse effects, particularly infection risks, to ensure the optimal administration of JAK inhibitors in patients.
  • Critically evaluate emerging therapeutic strategies for difficult-to-treat psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myopathies, and propose innovative approaches to optimize patient outcomes based on current advancements.

Target Audience

The online series is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians / American Medical Association (AMA)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Nurses / American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 2.75 ANCC contact hours.

Physician Assistants / American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

Activity Director and Faculty

Activity Director

Leonard H. Calabrese, DO
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH

Cassandra Calabrese, DO
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH

M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Rheumatology
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH

Additional Planners

Debra Kangisser, PA-C
Elizabeth (Betsy) Kirchner, DNP

Faculty

Rohit Aggarwal, MD, MS
Medical Director, Arthritis and Autoimmunity Center
Professor of Medicine
Co-director, UPMC Myositis Center
Division of Rheumatology and Clinical Immunology
University of Pittsburgh
Pittsburgh, PA

Jack Cush, MD
Executive Editor, RheumNow.com

Michelle Petri, MD, MPH
Professor of Medicine
Division of Rheumatology
Johns Hopkins University School of Medicine
Baltimore, MD

Michael Putman, MD, MSci
Assistant Professor of Medicine
Medical Director, Vasculitis Program
Medical College of Wisconsin
Milwaukee, WI

Christopher Ritchlin, MD, MPH
Director, Clinical Immunology Research Unit
University of Rochester Medicine
Rochester, NY

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Faculty Disclosure

In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated they have no relationship which, in the context of his/her presentation(s), could be perceived as a potential conflict of interest

Rohit Aggarwal, MD
CSL Behring
Astrazeneca Pharmaceuticals
Alexion
Kezar Life Sciences, Inc.
Octapharma
Kyverna
ArgenX
ANI Pharmaceuticals
Artasome
Cabaletta Bio
Capella Bioscience
Capstan Therapeutics, Inc.
Corbus
Galapagos
Horizon Therapeutics
I-Cell
Immunovant
Lilly
Manta Medicines Corporation
Novartis
Nuvig Therapeutics
NKarta
Teva
Tourmaline Bio
Verismo Therapeutics
Consulting
Boehringer Ingelheim
EMD Serono, Inc.
Janssen
Bristol-Myers Squibb Co.
Pfizer
PRoivant
Consulting
Research
Abbvie Pharmaceuticals Consulting (Ended: 01/01/2024)
Jubilant DraxImage, Inc.
Roivant Sciences Ltd. Consulting (Ended: 12/01/2024)
Orbus Pharmaceuticals Consulting (Ended: 12/01/2023)
Cassandra Calabrese, DO
Astra Zeneca
Sanofi-Regeneron
Consulting
Teaching and Speaking
Lilly Consulting (Ended: 12/01/2023)
Pfizer Consulting (Ended: 07/01/2023)
Leonard Calabrese, DO
Astra Zeneca Teaching and Speaking
Sanofi Aventis Consulting
Genentech/Roche Consulting
Advisor or review panel participant
Teaching and Speaking
Novartis Consulting
UCB
Janssen
Consulting
Teaching and Speaking
Abbvie Pharmaceuticals Consulting
J. Jack Cush, MD
Bristol-Myers Squibb Co.
Novartis
UCB
Abbvie Pharmaceuticals
Sanofi
Consulting
Advisor or review panel participant
M. Elaine Husni, MD
Lilly
Amgen
Bristol-Myers Squibb Co.
Janssen
AbbVie Pharmaceuticals
Consulting
Advisor or review panel participant
Novartis Pharmaceuticals Consulting
Advisor or review panel participant
Teaching and Speaking
Pfizer, Inc. Advisor or review panel participant
UCB, Inc. Consulting
Regeneron Consulting (Ended: 01/01/2024)
Advisor or review panel participant (Ended: 01/01/2024)
National Psoriasis Foundation Other activities from which remuneration is received or expected
Research
Elizabeth Kirchner, DNP
Lilly Consulting (Ended: 06/29/2023)
Pfizer Consulting (Ended: 11/09/2023)
Boehringer Ingelheim Advisor or review panel participant (Ended: 09/08/2022)
UCB Advisor or review panel participant (Ended: 10/17/2022)
Horizon Pharma Advisor or review panel participant (Ended: 09/08/2022)
Janssen Pharmaceuticals, Inc. Consulting (Ended: 12/07/2023)
RhAPP Teaching and Speaking
Michelle Petri
Aurinia Pharmaceuticals Teaching and Speaking (Ended: 12/31/2024)
Research
Exagen Diagnostics Research
GlaxoSmithKline Consulting
Research
Janssen Research (Ended: 12/31/2024)
Abbvie Pharmaceuticals Consulting (Ended: 01/01/2025)
Alexion
Duality Bio
Gentibio
iConPLC
Innovaderm Research
Consulting (Ended: 12/31/2024)
Amgen Consulting (Ended: 07/31/2024)
Anneion Bio
Astrazeneca Pharmaceuticals
Autolus
Bain Capital
Baobab Therapeutics
BioCryst Pharmaceuticals, Inc.
Boxer Capital
Caribou Biosciences Inc
CVS/Caremark
Escient Pharmaceuticals
Exo Therapeutics
Novartis
Ono Pharma USA
Owkin
Regeneron Pharmaceuticals
Seismic Therapeutic
Senti Biosciences
Steritas
Takeda
UCB
Variant Bio, Inc.
Vertex Pharmaceuticals
Zydus Pharmaceuticals (USA) Inc.
Consulting
Arthros-FocusMedEd Teaching and Speaking (Ended: 12/31/2023)
Atara Biotherapeutics Consulting (Ended: 10/30/2024)
Avoro Ventures Consulting (Ended: 04/11/2024)
Bavarian Nordic
EMD Serono, Inc.
Advisor or review panel participant
Biogen Idec Advisor or review panel participant (Ended: 12/31/2024)
Cabaletta Bio
Proviant
Sinomab Biosciences
Consulting (Ended: 01/31/2024)
CTI Clinical Trial & Consulting Services Advisor or review panel participant (Ended: 10/30/2024)
Ermium Consulting (Ended: 08/31/2024)
iCell Gene Therapeutics
Tenet Medicines Inc
Consulting (Ended: 11/30/2024)
IQVIA Advisor or review panel participant (Ended: 12/31/2023)
Kira Pharmaceuticals Consulting (Ended: 03/31/2023)
Nexstone Immunology Consulting (Ended: 03/31/2024)
Nimbus Lakshmi Consulting (Ended: 07/31/2023)
PPD Development Advisor or review panel participant (Ended: 02/28/2024)
Precision Biosciences Consulting (Ended: 06/30/2024)
TG Therapeutics Consulting (Ended: 05/31/2024)
Worldwide Clinical Trials Advisor or review panel participant (Ended: 10/30/2024)
Michael Putman, MD
Abbvie Pharmaceuticals Research (Ended: 12/01/2024)
Amgen Other activities from which remuneration is received or expected (Ended: 12/01/2024)
Research (Ended: 12/01/2024)
Astra Zeneca Other activities from which remuneration is received or expected (Ended: 12/01/2024)
Research
GSK Advisor or review panel participant (Ended: 12/01/2024)
Novartis Other activities from which remuneration is received or expected (Ended: 12/01/2024)
Research (Ended: 12/01/2024)
Christopher Ritchlin, MD
BMS
Novartis Pharmaceuticals
Janssen
Consulting
Research
Amgen Consulting (Ended: 01/01/2024)
UCB Consulting
Other activities from which remuneration is received or expected
Abbvie Pharmaceuticals Consulting
Advisor or review panel participant
MoonLake Immunotherapeutics Consulting

All other individuals have indicated no relationship which, in the context of their involvement, could be perceived as a potential conflict of interest.

Acknowledgment

The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:

Genentech
Janssen Scientific Affairs, LLC
UCB, Inc.


This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Department of Rheumatic & Immunologic Diseases, and Cleveland Clinic’s RJ Fasenmyer Center for Clinical Immunology.